vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Varex Imaging Corp (VREX). Click either name above to swap in a different company.
Varex Imaging Corp is the larger business by last-quarter revenue ($209.6M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 4.9%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 0.8%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Varex Imaging Corp is a global supplier of advanced imaging components and solutions, including X-ray tubes, digital flat panel detectors, and image processing software. Its products serve medical imaging, radiation oncology, and industrial non-destructive testing segments, with customers across key global markets.
ESPR vs VREX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $209.6M |
| Net Profit | — | $2.3M |
| Gross Margin | — | 33.3% |
| Operating Margin | 50.6% | 7.3% |
| Net Margin | — | 1.1% |
| Revenue YoY | 143.7% | 4.9% |
| Net Profit YoY | — | 866.7% |
| EPS (diluted) | $0.32 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $209.6M | ||
| Q4 25 | $168.4M | $228.9M | ||
| Q3 25 | $87.3M | $203.0M | ||
| Q2 25 | $82.4M | $212.9M | ||
| Q1 25 | $65.0M | $199.8M | ||
| Q4 24 | $69.1M | — | ||
| Q3 24 | $51.6M | $205.7M | ||
| Q2 24 | $73.8M | $209.1M |
| Q1 26 | — | $2.3M | ||
| Q4 25 | — | $12.2M | ||
| Q3 25 | $-31.3M | $-89.1M | ||
| Q2 25 | $-12.7M | $6.9M | ||
| Q1 25 | $-40.5M | $-300.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $-51.1M | ||
| Q2 24 | $-61.9M | $1.4M |
| Q1 26 | — | 33.3% | ||
| Q4 25 | — | 34.0% | ||
| Q3 25 | — | 33.3% | ||
| Q2 25 | — | 36.0% | ||
| Q1 25 | — | 34.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 32.6% | ||
| Q2 24 | — | 32.0% |
| Q1 26 | — | 7.3% | ||
| Q4 25 | 50.6% | 8.6% | ||
| Q3 25 | -11.4% | -39.8% | ||
| Q2 25 | 8.6% | 10.4% | ||
| Q1 25 | -34.0% | 5.6% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | 5.3% | ||
| Q2 24 | 3.5% | 4.4% |
| Q1 26 | — | 1.1% | ||
| Q4 25 | — | 5.3% | ||
| Q3 25 | -35.9% | -43.9% | ||
| Q2 25 | -15.4% | 3.2% | ||
| Q1 25 | -62.2% | -0.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | -24.8% | ||
| Q2 24 | -83.9% | 0.7% |
| Q1 26 | — | $0.05 | ||
| Q4 25 | $0.32 | $0.29 | ||
| Q3 25 | $-0.16 | $-2.15 | ||
| Q2 25 | $-0.06 | $0.17 | ||
| Q1 25 | $-0.21 | $-0.01 | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | $-1.25 | ||
| Q2 24 | $-0.33 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $125.6M |
| Total DebtLower is stronger | — | $367.6M |
| Stockholders' EquityBook value | $-302.0M | $476.9M |
| Total Assets | $465.9M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $125.6M | ||
| Q4 25 | $167.9M | $155.1M | ||
| Q3 25 | $92.4M | $152.6M | ||
| Q2 25 | $86.1M | $223.0M | ||
| Q1 25 | $114.6M | $212.6M | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | $200.5M | ||
| Q2 24 | $189.3M | $190.0M |
| Q1 26 | — | $367.6M | ||
| Q4 25 | — | $367.5M | ||
| Q3 25 | — | $367.5M | ||
| Q2 25 | — | $567.2M | ||
| Q1 25 | — | $567.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $443.4M | ||
| Q2 24 | — | $443.1M |
| Q1 26 | — | $476.9M | ||
| Q4 25 | $-302.0M | $472.6M | ||
| Q3 25 | $-451.4M | $455.3M | ||
| Q2 25 | $-433.5M | $549.7M | ||
| Q1 25 | $-426.2M | $540.2M | ||
| Q4 24 | $-388.7M | — | ||
| Q3 24 | $-370.2M | $529.1M | ||
| Q2 24 | $-344.2M | $581.2M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $465.9M | $1.1B | ||
| Q3 25 | $364.0M | $1.1B | ||
| Q2 25 | $347.1M | $1.4B | ||
| Q1 25 | $324.0M | $1.3B | ||
| Q4 24 | $343.8M | — | ||
| Q3 24 | $314.1M | $1.2B | ||
| Q2 24 | $352.3M | $1.3B |
| Q1 26 | — | 0.77× | ||
| Q4 25 | — | 0.78× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $-16.1M |
| Free Cash FlowOCF − Capex | — | $-26.8M |
| FCF MarginFCF / Revenue | — | -12.8% |
| Capex IntensityCapex / Revenue | 0.0% | 5.1% |
| Cash ConversionOCF / Net Profit | — | -7.00× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-16.1M | ||
| Q4 25 | $45.2M | $7.9M | ||
| Q3 25 | $-4.3M | $7.7M | ||
| Q2 25 | $-31.4M | $16.6M | ||
| Q1 25 | $-22.6M | $9.5M | ||
| Q4 24 | $-35.0M | — | ||
| Q3 24 | $-35.3M | $25.9M | ||
| Q2 24 | $-7.2M | $8.0M |
| Q1 26 | — | $-26.8M | ||
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | — | $9.8M | ||
| Q1 25 | — | $5.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | $19.9M | ||
| Q2 24 | $-7.3M | $3.3M |
| Q1 26 | — | -12.8% | ||
| Q4 25 | — | 1.0% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 4.6% | ||
| Q1 25 | — | 2.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | 9.7% | ||
| Q2 24 | -9.9% | 1.6% |
| Q1 26 | — | 5.1% | ||
| Q4 25 | 0.0% | 2.4% | ||
| Q3 25 | 0.0% | 3.1% | ||
| Q2 25 | 0.0% | 3.2% | ||
| Q1 25 | 0.0% | 2.1% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | 2.9% | ||
| Q2 24 | 0.1% | 2.2% |
| Q1 26 | — | -7.00× | ||
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
VREX
| Medical Segment | $144.8M | 69% |
| Industrial Segment | $64.8M | 31% |
